| 1 |
Kaplan AI, Mazor Y, Prott GM, Sequeira C, Jones MP, Malcolm A. Experiencing multiple concurrent functional gastrointestinal disorders is associated with greater symptom severity and worse quality of life in chronic constipation and defecation disorders. Neurogastroenterol Motil 2023;35:e14524. [PMID: 36578247 DOI: 10.1111/nmo.14524] [Reference Citation Analysis]
|
| 2 |
Thwaites PA, Burgell RE. Editorial: definition of factors associated with poor quality of life in patients with IBS-but where to from here? Aliment Pharmacol Ther 2023;57:723-4. [PMID: 36821756 DOI: 10.1111/apt.17391] [Reference Citation Analysis]
|
| 3 |
Mayntz SK, Peronard CRF, Søgaard J, Chang AY. The economic burden of diseases in the Nordic countries: A systematic review. Scand J Public Health 2023;:14034948231153025. [PMID: 36782401 DOI: 10.1177/14034948231153025] [Reference Citation Analysis]
|
| 4 |
Bosman MHMA, Weerts ZZRM, Snijkers JTW, Vork L, Mujagic Z, Masclee AAM, Jonkers DMAE, Keszthelyi D. The Socioeconomic Impact of Irritable Bowel Syndrome: An Analysis of Direct and Indirect Health Care Costs. Clin Gastroenterol Hepatol 2023:S1542-3565(23)00076-9. [PMID: 36731587 DOI: 10.1016/j.cgh.2023.01.017] [Reference Citation Analysis]
|
| 5 |
Schartner E. Warum dieses Buch? So klappt's mit der Verdauung 2023. [DOI: 10.1007/978-3-662-66434-6_1] [Reference Citation Analysis]
|
| 6 |
Pessarelli T, Sorge A, Elli L, Costantino A. The low-FODMAP diet and the gluten-free diet in the management of functional abdominal bloating and distension. Front Nutr 2022;9. [DOI: 10.3389/fnut.2022.1007716] [Reference Citation Analysis]
|
| 7 |
Carbone F, Van den Houte K, Besard L, Tack C, Arts J, Caenepeel P, Piessevaux H, Vandenberghe A, Matthys C, Biesiekierski J, Capiau L, Ceulemans S, Gernay O, Jones L, Maes S, Peetermans C, Raat W, Stubbe J, Van Boxstael R, Vandeput O, Van Steenbergen S, Van Oudenhove L, Vanuytsel T, Jones M, Tack J; DOMINO Study Collaborators, Domino Study Collaborators. Diet or medication in primary care patients with IBS: the DOMINO study - a randomised trial supported by the Belgian Health Care Knowledge Centre (KCE Trials Programme) and the Rome Foundation Research Institute. Gut 2022;71:2226-32. [PMID: 35483886 DOI: 10.1136/gutjnl-2021-325821] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 9.0] [Reference Citation Analysis]
|
| 8 |
Pushkina AV, Avalueva EB, Bakulin IG, Topanova AA, Klikunova KA, Lapinskii IV, Sitkin SI. Risk factors for various clinical variants of irritable bowel syndrome. jour 2022. [DOI: 10.31146/1682-8658-ecg-201-5-39-48] [Reference Citation Analysis]
|
| 9 |
Andresen V, Becker G, Frieling T, Goebel-Stengel M, Gundling F, Herold A, Karaus M, Keller J, Kim M, Klose P, Krammer H, Kreis ME, Kuhlbusch-Zicklam R, Langhorst J, Layer P, Lenzen-Großimlinghaus R, Madisch A, Mönnikes H, Müller-Lissner S, Rubin D, Schemann M, Schwille-Kiuntke J, Stengel A, Storr M, van der Voort I, Voderholzer W, Wedel T, Wirz S, Witzigmann H, Pehl C; In Zusammenarbeit mit:, Deutsche Gesellschaft für Allgemein- und Viszeralchirurgie (DGAV)/Chirurgische Arbeitsgemeinschaft für Coloproktologie (CACP), Deutsche Gesellschaft für Ernährungsmedizin (DGEM), Deutsche Gesellschaft für Naturheilkunde (DGNHK), Deutsche Gesellschaft für Geriatrie (DGG), Deutsche Gesellschaft für Koloproktologie (DGK), Deutsche Gesellschaft für Innere Medizin (DGIM), Deutsche Gesellschaft für Palliativmedizin e. V. (DGP), Deutsche Schmerzgesellschaft e. V., MAGDA Patientenforum (MAGDA). Aktualisierte S2k-Leitlinie chronische Obstipation der Deutschen Gesellschaft für Gastroenterologie, Verdauungs- und Stoffwechselkrankheiten (DGVS) und der Deutschen Gesellschaft für Neurogastroenterologie & Motilität (DGNM) – April 2022 – AWMF-Registriernummer: 021–019. Z Gastroenterol 2022;60:1528-72. [PMID: 36223785 DOI: 10.1055/a-1880-1928] [Reference Citation Analysis]
|
| 10 |
Yang C, Bai X, Hu T, Xue X, Su X, Zhang X, Wu T, Zhang M, Shen X, Dong X. Integrated metagenomics and targeted-metabolomics analysis of the effects of phenylalanine on loperamide-induced constipation in rats. Front Microbiol 2022;13:1018008. [DOI: 10.3389/fmicb.2022.1018008] [Reference Citation Analysis]
|
| 11 |
Wang K, Liu H, Liu J, Han L, Kang Z, Liang L, Jiang S, Meng N, Chen P, Xu Q, Wu Q, Hao Y. Factors related to irritable bowel syndrome and differences among subtypes: A cross-sectional study in the UK Biobank. Front Pharmacol 2022;13:905564. [DOI: 10.3389/fphar.2022.905564] [Reference Citation Analysis]
|
| 12 |
Sperber AD, Freud T, Abu-Freha N, Shibli F, Brun R, Bangdiwala SI, Palsson OS, Dickman R. Epidemiology of disorders of Gut-Brain interaction in Israel: Results from the Rome Foundation global epidemiology study. Neurogastroenterol Motil 2022;34:e14323. [PMID: 35072332 DOI: 10.1111/nmo.14323] [Reference Citation Analysis]
|
| 13 |
Pretorius L, Van Staden AD, Kellermann TA, Henning N, Smith C. Rooibos (Aspalathus linearis) alters secretome trace amine profile of probiotic and commensal microbes in vitro. J Ethnopharmacol 2022;297:115548. [PMID: 35850312 DOI: 10.1016/j.jep.2022.115548] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 14 |
Bellini M, Tosetti C, Rettura F, Morganti R, Lambiase C, Bassotti G, Visaggi P, Pancetti A, Benedetto E, de Bortoli N, Usai-Satta P, De Bastiani R. Translational Gap between Guidelines and Clinical Medicine: The Viewpoint of Italian General Practitioners in the Management of IBS. J Clin Med 2022;11. [PMID: 35807145 DOI: 10.3390/jcm11133861] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 15 |
Sharifi M, Safarpour AR, Barati-Boldaji R, Rahmati L, Karimi S, Bagheri Lankaran K. Post-Infectious Irritable Bowel Syndrome after an Epidemic of Gastroenteritis in South of Iran. Middle East J Dig Dis 2022;14:304-9. [PMID: 36619262 DOI: 10.34172/mejdd.2022.287] [Reference Citation Analysis]
|
| 16 |
Mourey F, Decherf A, Jeanne JF, Clément-Ziza M, Grisoni ML, Machuron F, Legrain-Raspaud S, Bourreille A, Desreumaux P. Saccharomyces cerevisiae I-3856 in irritable bowel syndrome with predominant constipation. World J Gastroenterol 2022; 28(22): 2509-2522 [DOI: 10.3748/wjg.v28.i22.2509] [Cited by in CrossRef: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 17 |
Duffy C, Pridgen WL, Whitley RJ. Gastric herpes simplex virus type 1 infection is associated with functional gastrointestinal disorders in the presence and absence of comorbid fibromyalgia: a pilot case-control study. Infection 2022. [PMID: 35445970 DOI: 10.1007/s15010-022-01823-w] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 18 |
Bielefeldt K. Cost of Constipation: A New Look With a Focus on New Medications. J Clin Gastroenterol 2022;56:249-56. [PMID: 33780224 DOI: 10.1097/MCG.0000000000001514] [Reference Citation Analysis]
|
| 19 |
Calderon G, Patel C, Camilleri M, James-Stevenson T, Bohm M, Siwiec R, Rogers N, Wo J, Lockett C, Gupta A, Xu H, Shin A. Associations of Habitual Dietary Intake With Fecal Short-Chain Fatty Acids and Bowel Functions in Irritable Bowel Syndrome. J Clin Gastroenterol 2022;56:234-42. [PMID: 33780215 DOI: 10.1097/MCG.0000000000001521] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 20 |
Yang Q, Wei ZC, Liu N, Pan YL, Jiang XS, Tantai XX, Yang Q, Yang J, Wang JJ, Shang L, Lin Q, Xiao CL, Wang JH. Predictive value of alarm symptoms in Rome IV irritable bowel syndrome: A multicenter cross-sectional study. World J Clin Cases 2022; 10(2): 563-575 [DOI: 10.12998/wjcc.v10.i2.563] [Cited by in CrossRef: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 21 |
Moverman MA, Puzzitiello RN, Pagani NR, Moon AS, Hart PA, Kirsch JM, Jawa A, Menendez ME. Functional somatic syndromes are associated with suboptimal outcomes and high cost after shoulder arthroplasty. J Shoulder Elbow Surg 2022;31:48-55. [PMID: 34116194 DOI: 10.1016/j.jse.2021.05.015] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
|
| 22 |
Pitcher CK, Farmer AD, Haworth JJ, Treadway S, Hobson AR. Performance and Interpretation of Hydrogen and Methane Breath Testing Impact of North American Consensus Guidelines. Dig Dis Sci 2022;67:5571-9. [PMID: 35366119 DOI: 10.1007/s10620-022-07487-8] [Reference Citation Analysis]
|
| 23 |
Karim MA, Al-Baz N, Haddad PM, Reagu SM, Alabdulla M. Buspirone in the management of refractory irritable bowel syndrome: A case report. Medicine (Baltimore) 2021;100:e28003. [PMID: 34941040 DOI: 10.1097/MD.0000000000028003] [Reference Citation Analysis]
|
| 24 |
Beinvogl B, Palmer N, Kohane I, Nurko S. Healthcare spending and utilization for pediatric Irritable Bowel Syndrome in a commercially insured population. Neurogastroenterol Motil 2021;33:e14147. [PMID: 33818857 DOI: 10.1111/nmo.14147] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
|
| 25 |
Livitz M, Friesen AS, Glynn EF, Schurman JV, Colombo JM, Friesen CA. Healthcare System-to-System Cost Variability in the Care of Pediatric Abdominal Pain-Associated Functional Gastrointestinal Disorders. Children (Basel) 2021;8:985. [PMID: 34828700 DOI: 10.3390/children8110985] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 26 |
Abedi SH, Fazlzadeh A, Mollalo A, Sartip B, Mahjour S, Bahadory S, Taghipour A, Rostami A. The neglected role of Blastocystis sp. and Giardia lamblia in development of irritable bowel syndrome: A systematic review and meta-analysis. Microb Pathog 2021;:105215. [PMID: 34592369 DOI: 10.1016/j.micpath.2021.105215] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 4.5] [Reference Citation Analysis]
|
| 27 |
Connolly MP, Kotsopoulos N, Vermeersch S, Patris J, Cassiman D. Estimating the broader fiscal consequences of acute hepatic porphyria (AHP) with recurrent attacks in Belgium using a public economic analytic framework. Orphanet J Rare Dis 2021;16:346. [PMID: 34348763 DOI: 10.1186/s13023-021-01966-3] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
|
| 28 |
Zheng H, Jin S, Shen YL, Peng WY, Ye K, Tang TC, Zhao J, Chen M, Li ZG. Chinese Herbal Medicine for Irritable Bowel Syndrome: A Meta-Analysis and Trial Sequential Analysis of Randomized Controlled Trials. Front Pharmacol 2021;12:694741. [PMID: 34385918 DOI: 10.3389/fphar.2021.694741] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
|
| 29 |
Madia VN, Messore A, Saccoliti F, Tudino V, De Leo A, De Vita D, Bortolami M, Scipione L, Pindinello I, Costi R, Di Santo R. Tegaserod for the Treatment of Irritable Bowel Syndrome. Antiinflamm Antiallergy Agents Med Chem 2020;19:342-69. [PMID: 31518227 DOI: 10.2174/1871523018666190911121306] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 5.0] [Reference Citation Analysis]
|
| 30 |
Yan R, Murphy M, Genoni A, Marlow E, Dunican IC, Lo J, Andrew L, Devine A, Christophersen CT. Does Fibre-fix provided to people with irritable bowel syndrome who are consuming a low FODMAP diet improve their gut health, gut microbiome, sleep and mental health? A double-blinded, randomised controlled trial.BMJ Open Gastroenterol. 2020;7. [PMID: 32816830 DOI: 10.1136/bmjgast-2020-000448] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 31 |
Chey WD, Lembo AJ, Yang Y, Rosenbaum DP. Efficacy of Tenapanor in Treating Patients With Irritable Bowel Syndrome With Constipation: A 26-Week, Placebo-Controlled Phase 3 Trial (T3MPO-2). Am J Gastroenterol 2021;116:1294-303. [PMID: 33337659 DOI: 10.14309/ajg.0000000000001056] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 5.5] [Reference Citation Analysis]
|
| 32 |
Ozair A, Kumar R, Singh BP, Ghoshal UC, Bhat V, Kirubakaran R. Antibiotics for treatment of irritable bowel syndrome in adults. Cochrane Database of Systematic Reviews 2021. [DOI: 10.1002/14651858.cd014569] [Reference Citation Analysis]
|
| 33 |
Ivashkin KV, Grechishnikova VR, Reshetova MS, Ivashkin VT. Irritable Bowel and Bacterial Overgrowth Syndromes: a Bacterial Link Hypothesis of Functional Disease. Rossijskij žurnal gastroènterologii, gepatologii, koloproktologii 2021;31:54-63. [DOI: 10.22416/1382-4376-2021-31-1-54-63] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 34 |
Holland AM, Bon-Frauches AC, Keszthelyi D, Melotte V, Boesmans W. The enteric nervous system in gastrointestinal disease etiology. Cell Mol Life Sci 2021;78:4713-33. [PMID: 33770200 DOI: 10.1007/s00018-021-03812-y] [Cited by in Crossref: 16] [Cited by in F6Publishing: 11] [Article Influence: 8.0] [Reference Citation Analysis]
|
| 35 |
Engsbro AL, Begtrup LM, Haastrup P, Storsveen MM, Bytzer P, Kjeldsen J, Schaffalitzky De Muckadell O, Jarbøl DE. A positive diagnostic strategy is safe and saves endoscopies in patients with irritable bowel syndrome: A five-year follow-up of a randomized controlled trial. Neurogastroenterol Motil 2021;33:e14004. [PMID: 33029843 DOI: 10.1111/nmo.14004] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
|
| 36 |
Bielefeldt K. Perceived Barriers to Treatment in Persons Treated for Functional Gastrointestinal Disease with Constipation. Dig Dis Sci 2021;66:739-50. [PMID: 32816211 DOI: 10.1007/s10620-020-06544-4] [Reference Citation Analysis]
|
| 37 |
van Lanen AS, de Bree A, Greyling A. Efficacy of a low-FODMAP diet in adult irritable bowel syndrome: a systematic review and meta-analysis. Eur J Nutr 2021;60:3505-22. [PMID: 33585949 DOI: 10.1007/s00394-020-02473-0] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 7.0] [Reference Citation Analysis]
|
| 38 |
Sperber AD, Bangdiwala SI, Drossman DA, Ghoshal UC, Simren M, Tack J, Whitehead WE, Dumitrascu DL, Fang X, Fukudo S, Kellow J, Okeke E, Quigley EMM, Schmulson M, Whorwell P, Archampong T, Adibi P, Andresen V, Benninga MA, Bonaz B, Bor S, Fernandez LB, Choi SC, Corazziari ES, Francisconi C, Hani A, Lazebnik L, Lee YY, Mulak A, Rahman MM, Santos J, Setshedi M, Syam AF, Vanner S, Wong RK, Lopez-Colombo A, Costa V, Dickman R, Kanazawa M, Keshteli AH, Khatun R, Maleki I, Poitras P, Pratap N, Stefanyuk O, Thomson S, Zeevenhooven J, Palsson OS. Worldwide Prevalence and Burden of Functional Gastrointestinal Disorders, Results of Rome Foundation Global Study. Gastroenterology 2021;160:99-114.e3. [PMID: 32294476 DOI: 10.1053/j.gastro.2020.04.014] [Cited by in Crossref: 496] [Cited by in F6Publishing: 503] [Article Influence: 248.0] [Reference Citation Analysis]
|
| 39 |
Fritsche E, Haarmann-Stemmann T, Kapr J, Galanjuk S, Hartmann J, Mertens PR, Kämpfer AAM, Schins RPF, Tigges J, Koch K. Stem Cells for Next Level Toxicity Testing in the 21st Century. Small 2021;17:e2006252. [PMID: 33354870 DOI: 10.1002/smll.202006252] [Cited by in Crossref: 17] [Cited by in F6Publishing: 19] [Article Influence: 5.7] [Reference Citation Analysis]
|
| 40 |
Erdrich S, Hawrelak JA, Myers SP, Harnett JE. A systematic review of the association between fibromyalgia and functional gastrointestinal disorders. Therap Adv Gastroenterol 2020;13:1756284820977402. [PMID: 33343707 DOI: 10.1177/1756284820977402] [Cited by in Crossref: 20] [Cited by in F6Publishing: 19] [Article Influence: 6.7] [Reference Citation Analysis]
|
| 41 |
Carco C, Young W, Gearry RB, Talley NJ, McNabb WC, Roy NC. Increasing Evidence That Irritable Bowel Syndrome and Functional Gastrointestinal Disorders Have a Microbial Pathogenesis. Front Cell Infect Microbiol 2020;10:468. [PMID: 33014892 DOI: 10.3389/fcimb.2020.00468] [Cited by in Crossref: 30] [Cited by in F6Publishing: 32] [Article Influence: 10.0] [Reference Citation Analysis]
|
| 42 |
Bu F, Chen R, Lin Z, Cao H, Robinson N, Liang N, Liu J. Chinese herbal medicine versus probiotics for irritable bowel syndrome: A systematic review and meta-analysis of randomized controlled trials. European Journal of Integrative Medicine 2020;38:101177. [DOI: 10.1016/j.eujim.2020.101177] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
|
| 43 |
Hamatani T, Fukudo S, Nakada Y, Inada H, Kazumori K, Miwa H. Randomised clinical trial: minesapride vs placebo for irritable bowel syndrome with predominant constipation. Aliment Pharmacol Ther 2020;52:430-41. [PMID: 32583907 DOI: 10.1111/apt.15907] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 2.3] [Reference Citation Analysis]
|
| 44 |
Black CJ, Ford AC. Global burden of irritable bowel syndrome: trends, predictions and risk factors. Nat Rev Gastroenterol Hepatol 2020;17:473-86. [PMID: 32296140 DOI: 10.1038/s41575-020-0286-8] [Cited by in Crossref: 127] [Cited by in F6Publishing: 104] [Article Influence: 42.3] [Reference Citation Analysis]
|
| 45 |
Mendoza López G, Becerra Torres EC. Síndrome de intestino irritable: un enfoque integral. Atención Familiar 2020;27:150. [DOI: 10.22201/facmed.14058871p.2020.3.75899] [Reference Citation Analysis]
|
| 46 |
Melchior C, Douard V, Coëffier M, Gourcerol G. Fructose and irritable bowel syndrome. Nutr Res Rev 2020;33:235-43. [PMID: 32122419 DOI: 10.1017/S0954422420000025] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
|
| 47 |
Herndon CC, Wang YP, Lu CL. Targeting the gut microbiota for the treatment of irritable bowel syndrome. Kaohsiung J Med Sci 2020;36:160-70. [PMID: 31782606 DOI: 10.1002/kjm2.12154] [Cited by in Crossref: 18] [Cited by in F6Publishing: 20] [Article Influence: 4.5] [Reference Citation Analysis]
|
